



## **Osiris Therapeutics to Present at UBS Global Life Sciences Conference**

**BALTIMORE, Maryland – September 15, 2006** – Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, will be presenting at the UBS Global Life Sciences Conference in New York City on September 25, 2006. The presentation is scheduled for 1:00 PM (Eastern Time). A live web cast may be accessed through the Company's website at [www.Osiris.com](http://www.Osiris.com). The presentation will be archived on the Osiris website for a limited time, under the Investors tab, beginning approximately three hours after the presentation.

### ***About Osiris Therapeutics***

Osiris Therapeutics, Inc. is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells Osteocel® for regenerating bone in orthopedic indications. Prochymal™ is in Phase 3 clinical trials and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. The Company's pipeline of internally developed biologic drug candidates under evaluation also includes Chondrogen™ for regenerating cartilage in the knee, and Provacel™, for repairing heart tissue following a heart attack. Osiris is a fully integrated company, having developed stem cell capabilities in research and development, manufacturing, marketing and distribution. Osiris has developed an extensive intellectual property portfolio to protect the company's technology in the United States and a number of foreign countries including 45 U.S. and 163 foreign patents owned or licensed. (OSIR-G)

### ***Forward Looking Statements***

This press release may contain forward-looking statements. These forward-looking statements may generally be identified by the use of the words "may," "will," "expects," "anticipates," "believes," "estimates," and similar expressions, and involve a number of risks and uncertainties. For a variety of reasons, actual results may differ materially from those described in or contemplated by any such forward-looking statement. Consequently, the reader is cautioned to consider all forward-looking statements in light of the risks to which they are subject.

**For additional information, please contact Lisa Rodemann at 410.522.5005, extension 610.**